Charles River Laboratories International (NYSE:CRL) Upgraded to Moderate Buy at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Charles River Laboratories International (NYSE:CRL) to a moderate buy rating in a research note released on Tuesday,Zacks.com reports.

Several other research firms have also recently issued reports on CRL. UBS Group raised their price target on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday, April 8th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, TD Cowen reduced their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $205.36.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $179.54 on Tuesday. The business’s 50-day simple moving average is $169.06 and its 200 day simple moving average is $182.62. The stock has a market cap of $8.86 billion, a price-to-earnings ratio of -60.66, a P/E/G ratio of 2.15 and a beta of 1.61. Charles River Laboratories International has a 12-month low of $99.80 and a 12-month high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. The business had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter last year, the business earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently modified their holdings of the business. Purpose Unlimited Inc. acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $698,000. Rockefeller Capital Management L.P. raised its position in shares of Charles River Laboratories International by 30.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,750 shares of the medical research company’s stock worth $349,000 after purchasing an additional 404 shares during the period. Eos Management L.P. acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $839,000. Corient Private Wealth LLC raised its position in shares of Charles River Laboratories International by 68.5% during the fourth quarter. Corient Private Wealth LLC now owns 17,628 shares of the medical research company’s stock worth $3,516,000 after purchasing an additional 7,166 shares during the period. Finally, SHP Wealth Management acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $85,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.